Skip to contentO
Oramed Pharmaceuticals Inc.
O
ORMPOramed Pharmaceuticals Inc. Q3 2018 · 10-Q
Revenue$617.00K$617.00K±0.0% vs Q3 2017 Net Income-$4.35M-$4.35MN/M vs Q3 2017 EPS Diluted$0.30$0.30+100.0% vs Q3 2017 Operating Income-$4,534,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Oramed Pharmaceuticals Inc. · CIK 1176309 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$3,805,000N/M Margins · derivedOperating margin-734.8%−385.6 pt vs Q3 2017
Net margin-705.7%−387.2 pt vs Q3 2017
ended May 31, 2018 · filed Jul 12, 2018 · 42 d after period end